Asklepios BioPharmaceutical Inc, a wholly-owned subsidiary of Bayer AG, has entered into a multi-year research collaboration and option agreement with ReCode Therapeutics Inc. Under the agreement, the companies will work together to discover genetic medicines that precisely target a disease. This will be done by developing technology for the use of single vectors as delivery vehicles for gene editing and DNA cargoes.
